Last reviewed · How we verify
NCT06367010
Clinical Efficacy of 125I Brachytherapy Combined With Anlotinib in Radioiodine Refractory Thyroid Carcinoma Patients
trial testing Iodine-125 brachytherapy combine with Anlotinib in Thyroid Neoplasms in 8 participants. Completed in 1 April 2024.
1 April 2024
Quick facts
| Lead sponsor | Jiangxi Provincial Cancer Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 8 |
| Start date | 1 January 2019 |
| Primary completion | 1 April 2024 |
| Estimated completion | 1 April 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Iodine-125 brachytherapy combine with Anlotinib
Conditions studied
- Thyroid Neoplasms — all drugs for Thyroid Neoplasms →
Sponsor
Jiangxi Provincial Cancer Hospital
Who can join
Eligibility, any sex, with Thyroid Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A retrospective analysis was conducted on patients with radioiodine-refractory thyroid carcinoma (RRTC) who underwent radioactive 125I seed implantation combined with anlotinib from January 2019 to October 2024 at Jiangxi Cancer Hospital. Data on tumor size changes before and after treatment, serological tests (including serum TG, TgAb, CTn, CEA, etc.), changes in patients' pain scores, and side effects were collected to evaluate the clinical efficacy and safety of this therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06367010
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Thyroid Neoplasms
Currently open trials in the same condition.
- NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting
- NCT07447089 — EMDR Integrative Group Protocol and Individual Treatment for Patients With Cancer: A Pilot Study · NA · recruiting
- NCT07010380 — Dual-Channel Near-Infrared Autofluorescence Imaging and AI Analysis to Locate Parathyroid Glands (PTFinder) · recruiting
- NCT07434206 — Safety and Efficacy of Dexmedetomidine in Controlling Hemodynamics During Resection of Active Thyroid Secreting Tumors · Phase 2, PHASE3 · active not recruiting
- NCT06398795 — Dual-port Trans-subclavian Thyroid Endoscopic Surgery · NA · recruiting
Other Jiangxi Provincial Cancer Hospital trials
Trials by the same sponsor.
- NCT07314255 — The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma · active not recruiting
- NCT07277764 — Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carc · Phase 2 · recruiting
- NCT06752239 — Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC · Phase 3 · recruiting
- NCT07085988 — Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma · Phase 2 · recruiting
- NCT06770699 — Tertiary Lymphoid Structures in Nasopharyngeal Carcinoma · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06367010 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiangxi Provincial Cancer Hospital
- Last refreshed: 16 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06367010.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing